FIELD: medicine.
SUBSTANCE: described are isolated human antibodies or humanized antibodies, or their functional fragments, specific with respect to epitope CD38. Presented are variable areas of heavy and light chain of described antibodies. Claimed is pharmaceutical composition, which contains described antibody, or its functional fragment. Claimed is method of treating malfunction or condition, connected with undesirable presence of CD38+ cells, which includes introduction of efficient quantity of claimed pharmaceutical composition to individual. Isolated epitope CD38 is described.
EFFECT: invention allows to mediate lysis of cells, which overexpress CD38, efficiently.
53 cl, 16 dwg, 6 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO MST1R AND THEIR APPLICATION | 2010 |
|
RU2534890C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| ANTI-GM-CSF ANTIBODIES AND USING THEM | 2006 |
|
RU2447085C2 |
| MOLECULES WHICH BIND TO 4-1BB | 2011 |
|
RU2710717C2 |
| ISOLATED ANTI-CD30 ANTIBODY (VERSIONS); HOST CELL, METHOD OF OBTAINING CHIMERIC OR HUMANISED VERSION OF ANTI-CD30 ANTIBODIES (VERSIONS), METHOD OF INHIBITING GROWTH OF CELLS CD30+ AND METHOD OF INHIBITING GROWTH OF TUMOUR CELLS EXPRESSING CD30 | 2006 |
|
RU2492186C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| ANTIBODIES TARGETING A RECEPTOR BOUND TO G-PROTEINS, AND METHODS FOR USE THEREOF | 2015 |
|
RU2725819C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT OR PREVENTION | 2013 |
|
RU2631804C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| ANTI-C4,4A ANTIBODIES AND THEIR USE | 2010 |
|
RU2577977C2 |
